Intraoperative marking of the tumour resection surface for improved radiation therapy planning in head and neck cancer: preclinical evaluation of a novel liquid fiducial marker.
feasibility studies
fiducial markers
mouth neoplasms
radiotherapy
Journal
Dento maxillo facial radiology
ISSN: 0250-832X
Titre abrégé: Dentomaxillofac Radiol
Pays: England
ID NLM: 7609576
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
pubmed:
12
9
2020
medline:
24
2
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
To evaluate a novel liquid fiducial marker for intraoperative marking of the tumour resection surface in oral cancer patients to facilitate precise postoperative delineation of the interface between the tumour resection border and reconstructed tissue for intensity-modulated radiation therapy. A total of 200 markers were created by injecting the volumes of 10 µl, 20 µl, 30 µl, 40 µl and 50 µl of a liquid marker composed of sucrose acetoisobutyrate (SAIB) and iodinated sucrose acetoisobutyrate (x-SAIB) into the soft tissue of porcine mandible segments. Visibility of the resulting markers was quantified by threshold-based segmentation of the marker volume in CT- and CBCT imaging and by a comparison of signal intensities in MRI. Even the lowest volume of SAIB-/x-SAIB investigated (10 µl) resulted in a higher visibility (CT SAIB/x-SAIB, which has recently become available as a Conformité Européenne (CE)-marked fiducial marker, provides an option for fast and reliable production of markers with excellent visibility in imaging modalities used in oral cancer radiation therapy (RT) planning routine.
Identifiants
pubmed: 32915672
doi: 10.1259/dmfr.20200290
pmc: PMC7923065
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20200290Références
Radiother Oncol. 2016 Oct;121(1):64-69
pubmed: 27443450
Radiother Oncol. 2015 Jul;116(1):82-6
pubmed: 25981050
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
J Craniomaxillofac Surg. 2015 Jul;43(6):758-62
pubmed: 25964005
Radiother Oncol. 2017 Mar;122(3):393-399
pubmed: 28104299
Radiother Oncol. 2010 Mar;94(3):286-91
pubmed: 20199818
Radiother Oncol. 2019 Feb;131:8-13
pubmed: 30773191
Int J Radiat Oncol Biol Phys. 1993 Jul 15;26(4):675-9
pubmed: 8331000
Med Phys. 2015 Jun;42(6):2818-26
pubmed: 26127034
Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):347-50
pubmed: 10030260
J Radiat Res. 2013 Jul;54 Suppl 1:i61-8
pubmed: 23824129
Eur J Surg Oncol. 2009 Jun;35(6):578-82
pubmed: 18938055
Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):579-84
pubmed: 8621281
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Transl Radiat Oncol. 2018 Aug 02;13:24-28
pubmed: 30258990
Radiother Oncol. 2013 Aug;108(2):181-9
pubmed: 23806188
Radiother Oncol. 2017 Apr;123(1):78-84
pubmed: 28245908
Br J Radiol. 2018 Dec;91(1092):20180236
pubmed: 29975152
Strahlenther Onkol. 2017 Dec;193(12):1039-1047
pubmed: 28808749
Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):529-34
pubmed: 9486600
Eur J Surg Oncol. 2014 Jul;40(7):830-4
pubmed: 24726879
Pract Radiat Oncol. 2019 Nov;9(6):e506-e515
pubmed: 31279938
Radiat Oncol. 2020 Mar 23;15(1):69
pubmed: 32248826
Clin Oncol (R Coll Radiol). 2014 Nov;26(11):671-6
pubmed: 24929648
Radiother Oncol. 2011 Aug;100(2):276-81
pubmed: 21511352
Radiology. 2001 Feb;218(2):510-6
pubmed: 11161170
Am J Surg. 2002 Oct;184(4):325-31
pubmed: 12383894
Clin Transl Oncol. 2018 Feb;20(2):160-168
pubmed: 28612199
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):494-500
pubmed: 18374516
Radiat Oncol. 2012 Oct 22;7:175
pubmed: 23088283
J Craniomaxillofac Surg. 2015 May;43(4):567-73
pubmed: 25841307
Strahlenther Onkol. 2019 Aug;195(8):756-763
pubmed: 31143995
Cancer. 2008 Feb 1;112(3):535-43
pubmed: 18076014
Clin Transl Radiat Oncol. 2018 Nov 23;14:47-50
pubmed: 30555941
Cancer Radiother. 2020 Jul;24(4):288-297
pubmed: 32179006